Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab.
Helbling
D
D
Borner
M
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000473:pathology / Q000628:therapy*; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000628:therapy*; D007262:Infusions, Intravenous; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D000077544:Panitumumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab